The Company

VIRxSYS Corporation (www.virxsys.com), a privately held biotech company developing gene therapies for HIV and genetic diseases, announced that it has acquired all the core technology and other assets from Intronn Inc., a leading company in the field of RNA biology and therapeutics.

Intronn is best known for developing and patenting spliceosome-mediated RNA trans-splicing (SMaRT™) technology, a new approach to genetic medicine. Unlike most RNA technologies that deploy RNA modifications as “gene-silencers” to block selected gene functions, the SMaRT™ technology reprograms gene expression at the RNA level by inserting a new sequence into a gene to repair mutations or change gene expression.

“We see tremendous synergy between our two technologies. SMaRT™ reinforces our successful RNA antisense approach in our VRX496 therapy,” said Dr. Rautsola. “Combining the VIRxSYS delivery platform with the SMaRT™ RNA reprogramming technology will help us create powerful new therapies more rapidly. Our initial focus will continue to be on HIV and genetic diseases. Intronn brings advanced pre-clinical programs in hemophilia and cardiovascular disease, which will integrate extremely well with our own programs in those areas. We also envision applications of SMaRT™ in a broad range of disease indications.”

About VIRxSYS
Founded in 1998, VIRxSYS is a private biotechnology company that focuses on the development of a novel lentiviral vector platform technology for the treatment of serious diseases such as HIV/AIDS and cardiovascular and genetic diseases. The Company exclusively licensed its patented, proprietary technology platform from The Johns Hopkins University (JHU) in Baltimore, Maryland where the original research was conducted. The Company also has been issued additional patents relating to the application and manufacture of the technology. More information regarding VIRxSYS can be found at www.virxsys.com. Details for the Phase II study may be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.